Published in Acta Otorhinolaryngol Ital on February 01, 2005
Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol (2014) 0.89
Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol (2010) 0.88
Diagnosis and treatment of a neck node swelling suspicious for a malignancy: an algorithmic approach. Int J Surg Oncol (2010) 0.77
Contrast-enhanced [18F] fluorodeoxyglucose-positron emission tomography-computed tomography as an initial imaging modality in patients presenting with metastatic malignancy of undefined primary origin. Indian J Nucl Med (2015) 0.77
Management of neck metastases of unknown primary origin united in two European centers. Eur Arch Otorhinolaryngol (2014) 0.77
Deep neck abscess as the predominant initial presentation of carcinoma of unknown primary: A case report. Oncol Lett (2014) 0.75
Squamous cell carcinoma metastatic to cervical lymph nodes from unknown primary origin: the impact of chemoradiotherapy. Chin J Cancer (2012) 0.75
Synchronous bilateral tonsil carcinoma: case presentation and review of the literature. Infect Agent Cancer (2017) 0.75
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
Incisional or excisional neck-node biopsy before definitive radiotherapy, alone or followed by neck dissection. Head Neck (1991) 2.07
Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist (2005) 2.01
Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer (1993) 1.71
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64
Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol (2000) 1.64
Cervical metastases from unknown primaries: radiotherapeutic management and appearance of subsequent primaries. Int J Radiat Oncol Biol Phys (1990) 1.52
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Ann Oncol (2001) 1.44
The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am (1999) 1.43
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol (2002) 1.40
Radiotherapy-induced thyroid disorders. Cancer Treat Rev (2004) 1.39
Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging (2002) 1.36
Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol (2002) 1.29
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer (2002) 1.24
Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev (2004) 1.21
Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg (2001) 1.18
Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control (2002) 1.18
Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck (1998) 1.17
Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst (1999) 1.13
Cervical lymph node metastasis: unknown primary cancer. Cancer (1973) 1.13
The unknown biology of the unknown primary tumour: a literature review. Ann Oncol (2003) 1.13
[Therapy pf cervical lymph node metastases of unknown primary tumor]. Strahlenther Onkol (1997) 1.12
Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. Int J Radiat Oncol Biol Phys (1986) 1.09
FDG PET detection of unknown primary tumors. J Nucl Med (2000) 1.08
Occult tonsillar carcinoma in the unknown primary. Laryngoscope (1998) 1.05
Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer (1999) 1.03
Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. Head Neck (1995) 1.03
Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys (2001) 1.02
Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg (1990) 0.98
Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol (2001) 0.93
Distant metastases from nasopharyngeal cancer. ORL J Otorhinolaryngol Relat Spec (2001) 0.93
The management of metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary. Am J Clin Oncol (1998) 0.93
The occult head and neck primary: to treat or not to treat? Clin Oncol (R Coll Radiol) (1997) 0.92
Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol (2002) 0.92
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol (2001) 0.92
Metastases to lymph nodes of the head and neck from an unknown primary site. Am J Surg (1977) 0.92
18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope (1998) 0.92
Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation. Int J Radiat Oncol Biol Phys (1997) 0.91
Bilateral synchronous tonsillar carcinoma in cervical cancer of unknown primary site (CUPS). Eur Arch Otorhinolaryngol (2003) 0.91
Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection. Int J Radiat Oncol Biol Phys (2001) 0.90
Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck. Otolaryngol Head Neck Surg (2000) 0.89
Combined surgery and postoperative radiotherapy for cervical lymph node metastases from an unknown primary tumour. Radiother Oncol (1998) 0.89
Radiation treatment of cervical lymph node metastases from an unknown primary: an analysis of outcome by treatment volume and other prognostic factors. Radiother Oncol (1995) 0.89
Screening unilateral tonsillectomy in the unknown primary. Laryngoscope (1995) 0.89
Epstein-Barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: an aid for differentiating the primary site. Head Neck (2000) 0.88
2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg (2000) 0.87
Unknown primary tumours. Cancer Treat Rev (1994) 0.87
The violated neck: cervical node biopsy prior to definitive treatment. Otolaryngol Head Neck Surg (1986) 0.87
Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys (1992) 0.87
Cervical metastases from an unknown primary tumor. Radiology (1974) 0.86
Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope (2002) 0.86
Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head and neck mucosal site treated with radiation therapy with palliative intent. Radiother Oncol (2001) 0.86
Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT. Radiology (1996) 0.86
Cancer in neck nodes with unknown primary site: role of mucosal radiotherapy. Head Neck (1991) 0.85
Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. Head Neck (1998) 0.84
Treatment of metastatic neck nodes secondary to an occult epidermoid carcinoma of the head and neck. Laryngoscope (1987) 0.84
Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary? Int J Radiat Oncol Biol Phys (1997) 0.84
Can positron emission tomography improve the quality of care for head-and-neck cancer patients? Int J Radiat Oncol Biol Phys (2001) 0.84
Metastatic carcinoma in the cervical lymph nodes from an occult primary: a conservative approach to the role of radiotherapy. Int J Radiat Oncol Biol Phys (1990) 0.84
Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol (2003) 0.84
Cervical lymph node metastases from an unknown primary. Int J Radiat Oncol Biol Phys (1979) 0.84
Fluorescence-guided biopsy in the diagnosis of an unknown primary cancer in patients with metastatic cervical lymph nodes. Ann Otol Rhinol Laryngol (1999) 0.83
Metastatic squamous cell carcinoma to cervical lymph nodes from unknown primary mucosal sites. Head Neck (1994) 0.83
Metastatic cervical adenopathy from tumors of unknown origin: the role of CT. Radiology (1984) 0.83
Cervical metastases of occult origin: the impact of combined modality therapy. Am J Surg (1994) 0.82
Squamous cell carcinoma of the head and neck: management after excisional biopsy of a solitary metastatic neck node. Int J Radiat Oncol Biol Phys (1993) 0.82
The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck (2003) 0.82
Outcome of ipsilateral treatment for patients with metastases to neck nodes of unknown origin. Acta Oncol (2001) 0.81
Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. Cancer (1989) 0.81
Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma. Head Neck (2002) 0.81
Unknown primary squamous cell carcinoma metastatic to the neck. Arch Otolaryngol Head Neck Surg (1990) 0.81
Cervical metastasis of unknown origin: a series of 72 patients. Acta Otolaryngol (2002) 0.80
Metastatic squamous cell carcinoma of the neck from an unknown primary: management options and patterns of relapse. Head Neck (2002) 0.80
[Diagnosis and treatment of 39 patients with cervical lymph node metastases of squamous cell carcinoma of unknown primary origin, referred to Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1979-98]. Ned Tijdschr Geneeskd (2000) 0.80
Management and outcome of cervical lymph node metastases of unknown primary sites: a retrospective study. Br J Oral Maxillofac Surg (2002) 0.80
Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography. Eur J Nucl Med Mol Imaging (2002) 0.79
Guidelines for radiotherapeutic techniques for cervical metastases from an unknown primary. Int J Radiat Oncol Biol Phys (1986) 0.79
Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope (1992) 0.78
Metastatic squamous cell carcinoma in cervical lymph nodes from an unknown primary tumour: prognostic factors. Clin Otolaryngol Allied Sci (1998) 0.78
Cervical metastasis from the unknown primary tumor. Eur Arch Otorhinolaryngol (1995) 0.78
Neck dissection and ipsilateral radiotherapy in the management of cervical metastatic carcinoma from an unknown primary. Aust N Z J Surg (2000) 0.78
Unknown primary detected by FDG-PET. A review of the present indications of FDG-PET in head and neck cancers. Acta Otorhinolaryngol Belg (2002) 0.77
Hyperthermia and radiotherapy for inoperable squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site. Int J Hyperthermia (2000) 0.76
Unknown primary of the head and neck. J Laryngol Otol (1996) 0.76
[Metastatic cervical adenopathies of unknown primary site. Long-term course]. Ann Otolaryngol Chir Cervicofac (1996) 0.76
Malignant cervical lymphadenopathy due to an unknown primary. Clin Radiol (1980) 0.76
[Head and neck lymph node metastases from unknown primary site]. Otolaryngol Pol (2000) 0.76
[A study of cervical metastases from unknown primary tumor]. Acta Otorrinolaringol Esp (2002) 0.75
[Cervical lymph node metastasis from an unknown primary tumor]. Nihon Jibiinkoka Gakkai Kaiho (2000) 0.75
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer (2001) 2.09
Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol (2001) 2.03
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol (2005) 1.72
Rheumatoid factors as a cause for false positive IgM anti-toxoplasma fluorescent tests. A technique for specific results. Rev Inst Med Trop Sao Paulo (1973) 1.68
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.52
Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med (1999) 1.47
Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat (2009) 1.41
Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int (1995) 1.40
Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int (1994) 1.38
Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. Ann Oncol (1993) 1.37
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.24
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol (2008) 1.23
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.23
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20
Nipple-sparing mastectomy: risk of nipple-areolar recurrences in a series of 579 cases. Breast Cancer Res Treat (2008) 1.19
Oncoplastic techniques in the conservative surgical treatment of breast cancer. Breast Cancer (2000) 1.19
Protection against Chlamydia psittaci in mice conferred by Lyt-2+ T cells. Immunology (1992) 1.18
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) (2005) 1.13
Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. Ann Oncol (2012) 1.07
Fine-needle aspiration of parotid masses. Cancer (1993) 1.07
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol (2006) 1.06
The requirements of a specialist Breast Centre. Eur J Cancer (2013) 1.04
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol (2005) 1.03
Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutat (2000) 1.03
Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. Eur J Cancer (2003) 1.02
In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol (1995) 1.01
Complications of breast-cancer radiotherapy. Clin Oncol (R Coll Radiol) (2006) 1.01
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer (1997) 1.01
Immunoelectrophoretic analysis of the antigenic components of Bacillus megaterium. J Bacteriol (1967) 0.98
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol (2000) 0.98
Diffusion tensor magnetic resonance imaging of the normal breast: reproducibility of DTI-derived fractional anisotropy and apparent diffusion coefficient at 3.0 T. Radiol Med (2012) 0.97
Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept. Eur J Nucl Med Mol Imaging (2006) 0.97
Potential markers of tongue tumor progression selected by cDNA microarray. Int J Immunopathol Pharmacol (2005) 0.97
Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol (2005) 0.96
Treatment of malignant neoplasms of the parotid gland. Otolaryngol Head Neck Surg (1999) 0.96
Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? J Clin Pathol (1994) 0.96
Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol (2001) 0.96
Dosimetric accuracy assessment of a treatment plan verification system for scanned proton beam radiotherapy: one-year experimental results and Monte Carlo analysis of the involved uncertainties. Phys Med Biol (2013) 0.95
Identification of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface. J Virol (2000) 0.95
Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. J Natl Cancer Inst (2004) 0.95
A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients. J Neurol (1997) 0.94
Papillary carcinoma in thyroglossal duct remnants: presentation of four cases and decision procedure for prophylactic thyroid gland dissection. Oncol Rep (2000) 0.94
Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer (1991) 0.93
Excision of oral leukoplakias by CO2 laser on an out-patient basis: a useful procedure for prevention and early detection of oral carcinomas. Tumori (1986) 0.93
Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer (1999) 0.92
Structural peculiarities of a truncated V kappa III immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol (1996) 0.92
[Intraoperative radiotherapy (IORT) in treatment of breast carcinoma--a new therapeutic alternative within the scope of breast-saving therapy? Current status and future prospects. Report of experiences from the European Institute of Oncology (EIO), Mailand]. Strahlenther Onkol (2001) 0.92
Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood (1999) 0.92
Skin reactivity to dinitrochlorobenzene in cancer patients. Neoplasma (1980) 0.92
Post-operative radiotherapy in non-small-cell lung cancer: more questions than answers. Br J Cancer (1996) 0.91
Diagnostic information from serological tests in human toxoplasmosis. III.--Hemagglutination titers paradoxical decrease in acute infections. Rev Inst Med Trop Sao Paulo (1978) 0.91
Does fecal diversion offer any chance for spontaneous closure of the radiation-induced rectovaginal fistula? Int J Gynecol Cancer (2007) 0.90
Small sized phyllodes tumor of the breast. Eur J Surg Oncol (1990) 0.90
Oral leukoplakias: to treat or not? Oral Oncol (1997) 0.90
Endovascular treatment of bacterial intracranial aneurysms. Neuroradiology (1996) 0.90
When mastectomy becomes inevitable: the nipple-sparing approach. Breast (2005) 0.89
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. Ann Oncol (2000) 0.89
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol (2006) 0.89
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Eur J Cancer (2006) 0.88
Sentinel node biopsy in head and neck cancer. Ann Surg Oncol (2001) 0.88
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol (2005) 0.88
The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med (2013) 0.88
Sebaceous lymphadenoma of salivary gland: a case report and a review of the literature. Acta Otorhinolaryngol Ital (2007) 0.88
Cardiac and humoral changes induced by recreational scuba diving. Undersea Hyperb Med (1999) 0.88
A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer (2005) 0.87
Retrospective comparison of conservative and radical neck dissection in laryngeal cancer. Ann Otol Rhinol Laryngol (1981) 0.87
Intra- and interobserver agreement and impact of arterial input selection in perfusion CT measurements performed in squamous cell carcinoma of the upper aerodigestive tract. AJNR Am J Neuroradiol (2009) 0.87
Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Ann N Y Acad Sci (1995) 0.87
Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.87
Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med (1998) 0.87
Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. Eur J Cancer (2005) 0.86
p53 mutations and DNA ploidy in colorectal adenocarcinomas. Anal Cell Pathol (1998) 0.86
Oral vinorelbine: feasibility and safety profile. Ann Oncol (2001) 0.86
Quality of life in patients with chordomas/chondrosarcomas during treatment with proton beam therapy. J Radiat Res (2013) 0.85
Role of sentinel lymph node biopsy in oral cancer. Acta Otorhinolaryngol Ital (2006) 0.85
Iatrogenic lumbar pseudomeningocele. Zentralbl Neurochir (1986) 0.85
Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res (1994) 0.85
Surfing prognostic factors in head and neck cancer at the millennium. Oral Oncol (1999) 0.85
Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett (1994) 0.84
Assessment of pulmonary fibrosis after radiotherapy (RT) in breast conserving surgery: comparison between conventional external beam RT (EBRT) and intraoperative RT with electrons (ELIOT). Technol Cancer Res Treat (2011) 0.84
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. Ann Oncol (2012) 0.84
Enterotoxin gene profiles of Staphylococcus aureus isolated from milk and dairy products in Italy. Lett Appl Microbiol (2013) 0.84
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene (1997) 0.84
Transfection of human mutated K-ras in mouse NIH-3T3 cells is associated with increased cloning efficiency and DNA aneuploidization. Int J Cancer (1996) 0.84
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer (1998) 0.84
Automated fiducial localization in CT images based on surface processing and geometrical prior knowledge for radiotherapy applications. IEEE Trans Biomed Eng (2012) 0.84